9.07
+0.44%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Airdoc Technology Co
Its shares trade on HKEX under the ticker 2251.HK. It has been listed since 5 November 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥202.0m and a net loss of CN¥29.1m. At that date it held total assets of CN¥1.53bn and shareholders' equity of CN¥1.43bn.
Beijing Airdoc Technology Co. Ltd. is an AI-based medical device company, which engages in the provision of AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-11-05. The firm's main product is Airdoc-AIFUNDUS 1.0. The firm's product can be used in the diagnosis of glaucoma, cataract, ICVD and ASCVD, diabetic retinopathy of pregnancy, hypertensive retinopathy of pregnancy and other diseases. In addition, the Company has developed a deep pipeline of other Software-as-a-medical devices (SaMDs) and health risk assessment solutions to address various healthcare needs for the whole population, including hospitals, community clinics, health checkup centers, insurance companies, optometry centers and pharmacies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 5 Nov 2021
- Employees
- 369
- Website
- airdoc.com ↗
Leadership
Pay as last reported
- Mr. Dalei ZhangExecutive Chairman of the Board, Chief Executive Officer, since 2015CN¥469,000
- Dr. Chao HeChief Technology Officer, Executive Director, since 2018
- Mr. Yong QinExecutive Director
- Ms. Lin WangExecutive Director, since 2023
- Mr. Mingqiang ChenChief Research and Development Officer, since 2015CN¥703,000
- Ms. Lai Shan SoJoint Company Secretary
- Ms. Xinfeng WangJoint Company Secretary
- Mr. Yanlin HuangNon-Executive Independent Director
- Mr. Ho Yin NgNon-Executive Independent Director
- Mr. Yangfeng WuNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Airdoc-AIFUNDUS 1.0 detects glaucoma and diabetic retinopathy using AI technology.
- Beijing Airdoc employs 369 full-time staff in the Health Care sector.
- The company's AI solutions serve hospitals, clinics, and insurance companies across China.
Weaknesses
- The company's product focuses on retina-based diagnostics limiting broader medical applications.
- Beijing Airdoc's IPO in 2021 may face challenges in scaling operations.
- Airdoc-AIFUNDUS 1.0 is limited to specific diseases like cataract and ICVD.
Opportunities
- Expanding AI solutions to address more health conditions beyond retina diagnostics.
- Growing demand for AI in healthcare across China's aging population.
- Developing partnerships with more hospitals and health checkup centers nationwide.
Threats
- Increasing competition in the AI medical device sector in China.
- Regulatory changes affecting AI-based diagnostic tools in Health Care.
- Potential market saturation in retina-based diagnostic solutions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.